To determine the efficacy of Temozolomide defined as progression-free
survival at 6 months and safety of Temozolomide when administered orally,
once a day for 5 days repeated every 28 days in the treatment of patients
with GBM (Glioblastoma Multiforme) or AA (Anaplastic Astrocytoma) at first
relapse. A reference agent procarbazine is included in the study of
patients with GBM to verify that objective responses can be obtained using
the reference agent.
No Sub Projects information available for 5M01RR000037-37 0701
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5M01RR000037-37 0701
Patents
No Patents information available for 5M01RR000037-37 0701
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5M01RR000037-37 0701
Clinical Studies
No Clinical Studies information available for 5M01RR000037-37 0701
News and More
Related News Releases
No news release information available for 5M01RR000037-37 0701
History
No Historical information available for 5M01RR000037-37 0701
Similar Projects
No Similar Projects information available for 5M01RR000037-37 0701